Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novartis Ag ADR
(NY:
NVS
)
113.79
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Oct 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novartis Ag ADR
< Previous
1
2
3
4
5
6
7
8
9
...
41
42
Next >
Novartis Reveals Promising Gene Therapy Data for Treating Spinal Muscular Atrophy in Older Children
March 04, 2024
Novartis' Zolgensma gene therapy for spinal muscular atrophy latest SMART Phase 3b study reveals safety, efficacy, and significant milestones achieved. $1.21 billion sales reported in FY2023.
Via
Benzinga
3 Stocks Primed for Exponential Returns by 2034
March 01, 2024
As investors, It's always good to look at things long-term. Here are three stocks that are primed for exponential returns in ten years.
Via
InvestorPlace
2 Dividend Stocks to Buy and Hold Forever
February 29, 2024
These businesses look too strong to fail.
Via
The Motley Fool
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields
February 28, 2024
A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year.
Via
Benzinga
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
February 27, 2024
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...
Via
Newsfile
5 Tips to Manage Heart Health After a Heart Attack
February 23, 2024
(BPT) - By Dr. Norman Lepor
Via
Brandpoint
Looking Into Novartis's Recent Short Interest
February 22, 2024
Via
Benzinga
Celldex Stock Hits 11-Month High, Up 19%, On A Promising New Hives Treatment
February 26, 2024
The company tested its treatment in chronic spontaneous urticaria. Almost 38% of patients had "complete control" after 12 weeks.
Via
Investor's Business Daily
This Drug By Roche And Novartis Reduces Allergic Reactions Across Multiple Foods For People With Food Allergies
February 26, 2024
Results from Roche's Phase 3 OUtMATCH study on Xolair for multi-food allergies. Published in NEJM, the study reveals increased tolerance in patients aged 1-55. FDA-approved expanded use for...
Via
Benzinga
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
February 22, 2024
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.
Via
Talk Markets
Move Over Magnificent 7, Say Hello to the GRANOLAS
February 22, 2024
Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods.
Via
InvestorPlace
Exit Now! 3 Biotech Stocks to Sell in February 2024
February 21, 2024
These biotech stocks to sell represent incredibly risky bets, amidst the sector's volatility and looming economic unpredictability.
Via
InvestorPlace
22 Blue-Chip European Dividend Growth Stocks
February 16, 2024
A discussion of insights on European dividend growth stocks.
Via
Talk Markets
What The Future Holds For Google's 'Other Bets'
February 16, 2024
Alphabet's far-ranging Other Bets tickle imaginations, but they've piled up huge losses. Google stock could benefit as discipline is imposed.
Via
Investor's Business Daily
7 Contrarian Biotech Stocks to Consider Amid Sector Weakness
February 15, 2024
Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts.
Via
InvestorPlace
The 3 Biotech Stocks That Could Make Your February Unforgettable
February 15, 2024
After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks.
Via
InvestorPlace
Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst Says
February 14, 2024
Biogen's Leqembi launch challenges impact stock growth; Spinraza faces competition. Analyst lowers price target to $316, citing uncertainties.
Via
Benzinga
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
February 14, 2024
From
Erasca, Inc.
Via
GlobeNewswire
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Appoints Liat Halpert as Head of Business Development, Sales
February 13, 2024
Via
Investor Brand Network
How Cytokinetics Overcame Two Setbacks And Doubled Its Stock Price Over A Month
February 08, 2024
Cytokinetics is looking to take on Bristol Myers Squibb in treating a heart disease.
Via
Investor's Business Daily
JP Morgan's Bullish View On This Chinese Biotech, Says Pullback Creates Entry Point
February 06, 2024
BeiGene's JP Morgan coverage highlights upside in valuation post-pullback. Brukinsa's success and Tevimbra's potential add to the optimism. Overweight rating, $185 price target.
Via
Benzinga
Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B
February 06, 2024
Novartis' €2.7 billion public takeover offer for MorphoSys, unlocking a promising oncology pipeline with pelabresib and tulmimetostat.
Via
Benzinga
Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion
February 05, 2024
Novartis will add to its cancer treatment pipeline with via the German biotech.
Via
Investor's Business Daily
Drug Maker AbbVie Stock Sees RS Rating Jump To 81
February 05, 2024
AbbVie stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an increase from 78 to 81.
Via
Investor's Business Daily
Why Is MorphoSys (MOR) Stock Up 50% Today?
February 05, 2024
News of a potential takeout bid for any company usually leads to a big surge. That's what investors are seeing today with MOR stock.
Via
InvestorPlace
MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer
February 05, 2024
Novartis is in advanced talks to acquire MorphoSys and appears to be beating out Incyte Corporation which has also made an offer to acquire MorphoSys. MorphoSys produces a lymphoma drug, Monjuvi, sold...
Via
Benzinga
3 Fabulous Dividend Stocks to Buy in February
February 04, 2024
These stocks offer great dividends and more.
Via
The Motley Fool
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
February 02, 2024
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review
February 02, 2024
The Dow led the major indexes higher. Big techs diverged on results.
Via
Investor's Business Daily
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Novartis Ag (NVS) Q4 2023 Earnings Call Transcript
January 31, 2024
NVS earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
< Previous
1
2
3
4
5
6
7
8
9
...
41
42
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.